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Summary
Background: Decreased activation of the hypothalamus—pituitary—adrenal (HPA) axis in re-
sponse to stress is suspected to be a vulnerability factor for posttraumatic stress disorder (PTSD).
Previous studies showed inconsistent findings regarding the role of cortisol in predicting PTSD. In
addition, no prospective studies have examined the role of dehydroepiandrosterone (DHEA), or its
sulfate form DHEAS, and the cortisol-to-DHEA(S) ratio in predicting PTSD. In this study, we tested
whether acute plasma cortisol, DHEAS and the cortisol-to-DHEAS ratio predicted PTSD symptoms
at 6 weeks and 6 months post-trauma.
Methods: Blood samples of 397 adult level-1 trauma center patients, taken at the trauma
resuscitation room within hours after the injury, were analyzed for cortisol and DHEAS levels.
PTSD symptoms were assessed at 6 weeks and 6 months post-trauma with the Clinician Adminis-
tered PTSD Scale.
Results: Multivariate linear regression analyses showed that lower cortisol predicted PTSD
symptoms at both 6 weeks and 6 months, controlling for age, gender, time of blood sampling,
injury, trauma history, and admission to intensive care. Higher DHEAS and a smaller cortisol-to-
DHEAS ratio predicted PTSD symptoms at 6 weeks, but not after controlling for the same
variables, and not at 6 months.
Conclusions: Our study provides important new evidence on the crucial role of the HPA-axis in
response to trauma by showing that acute cortisol and DHEAS levels predict PTSD symptoms in
survivors of recent trauma.
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Injury victims presenting to an emergency room have an
increased risk of developing trauma-related psychopathol-
ogy, such as posttraumatic stress disorder (PTSD). Prevalence
rates of PTSD following a traffic accident, one of the most
common injury causing traumatic events (de Vries and Olff,
2009), vary greatly, from 8—45% at 1 month to 7—26% at 12
months (for a review, see Heron-Delaney et al., 2013). To
explain why some develop PTSD and others do not, studies
have examined the role of the hypothalamus—pituitary—
adrenal (HPA) axis (Delahanty et al., 2000, 2003, 2005;
McFarlane et al., 1997, 2011; Resnick et al., 1995, 1997;
Shalev et al., 2008; Yehuda et al., 1998b). It has
been hypothesized that an insufficient activation of the
HPA-axis in response to stress serves as vulnerability for PTSD
(Yehuda et al., 1998a; Yehuda, 2002). During acute stress, the
hypothalamus secretes corticotrophin-releasing hormone.
This in turn stimulates the pituitary gland to release adre-
nocorticotropic hormone, which leads to the production of
glucocorticoids (cortisol) and dehydroepiandrosterone
(DHEA) by the adrenal cortex (Vinson et al., 2007). Cortisol
suppresses metabolic, immuno- and neurodefensive pro-
cesses to adequately cope with the stressor, and triggers a
negative feedback loop when sufficient circulating levels are
reached. Low levels of circulating cortisol have been found to
be a vulnerability factor for developing PTSD symptoms,
either directly (Delahanty et al., 2003) or indirectly through
prior trauma exposure (Resnick et al., 1995; Yehuda et al.,
1998b). They fail to trigger the negative feedback loop, thus
prolonging the adrenergic response, which may exacerbate
consolidation of the traumatic memory. This may lead to
intrusive symptoms, which may increase the risk for PTSD
(Yehuda, 2002).
Whereas high cortisol has catabolic properties, DHEA and
its sulfate form DHEAS have been found to possess anabolic,
neuroprotective and antiglucocorticoid effects, showing
neurogenerative effects in the hippocampus (Karishma and
Herbert, 2002) and protection against the neurotoxic effects
of cortisol in studies in rodents (Kaminska et al., 2000;
Kimonides et al., 1998, 1999). This may contribute to
an upregulation of HPA-axis responses as well as mitigate
possible deleterious effects of high cortisol levels on the
brain in PTSD (Rasmusson et al., 2003). As such, it may
be hypothesized that dysregulations in the HPA-axis function
associated with PTSD may also be evident in an abnormal
DHEA-response. DHEAS is much more abundant than DHEA,
because DHEAS has longer half-life and lower clearance
(Lennartsson et al., 2012). Because DHEAS levels are also
more stable and show no diurnal variation (Kroboth et al.,
1999), they are often preferred in studies on long term
effects of stress. Studies on acute stress, on the other hand,
often assess DHEA, since DHEAS serves as a reservoir for
DHEA biosynthesis and DHEA rather than DHEAS is expected
to respond to acute psychosocial stress (Izawa et al., 2008;
Morgan et al., 2004; Oberbeck et al., 1998; Pico-Alfonso
et al., 2004; Shirotsuki et al., 2009). However, in a recent
study, although the response of DHEA was more pronounced,
both DHEA and DHEAS were found to increase in response
to acute psychosocial stress (Lennartsson et al., 2012).
In addition, DHEAS was found to increase in response tolow, but not high, intensity military stress exposure
(Morgan et al., 2004; Taylor et al., 2007). Cortisol and
DHEA(S) are often addressed as a ratio, representing
the balance between anabolic and catabolic hormones
(Maninger et al., 2009). A high ratio of cortisol-to-DHEA(S),
or conversely a low DHEA(S)-to-cortisol ratio, represents a
catabolic balance. A low cortisol-to-DHEA(S) ratio, or a
high DHEA(S)-to-cortisol ratio, reflects an anabolic balance.
A higher cortisol-to-DHEA ratio has been linked to a
chronic stress response in depressed adolescents and adults
(Goodyer et al., 1998; Young et al., 2002), as well as more
resilient functioning in both maltreated and non-maltreated
children (Cicchetti and Rogosch, 2007), whereas a higher
DHEAS-to-cortisol ratio was positively correlated with fewer
dissociative symptoms after prolonged and extreme
training stress (Morgan et al., 2004; Taylor et al., 2007).
Thus, previous findings are inconclusive with respect to the
role of the cortisol-to-DHEA(S) ratio in the onset of psychia-
tric disorders such as PTSD.
Findings from prospective studies on acute cortisol levels as
a predictor for PTSD so far are inconsistent. Some studies have
found that low cortisol levels immediately or in the first days
following trauma predict PTSD diagnosis (Delahanty et al.,
2000; McFarlane et al., 1997) or symptoms (Aardal-Eriksson
et al., 2001; Ehring et al., 2008; McFarlane et al., 2011). In
some of these studies, however, the association disappeared
when controlling for possible confounding variables, such as
injury severity and history of PTSD (Delahanty et al., 2000),
and time of the accident or blood sampling (McFarlane et al.,
1997). Other studies found no direct relationship between
initial cortisol and subsequent PTSD (Bonne et al., 2003;
McFarlane et al., 1997; Resnick et al., 1995; Shalev et al.,
2008). Variations in methodology, for example, when (i.e.,
immediately post-trauma up to several days after the event) or
how (i.e., saliva, urine or plasma) cortisol was measured,
might explain these differences. Lack of power due to a small
sample size has been referred to by some studies as a possi-
bility for not finding a significant association (Delahanty et al.,
2000; Ehring et al., 2008). Therefore, it has been argued that
the predictive effect of cortisol should be replicated in large,
consecutively recruited samples, taking into account the
important confounders. Until now, no prospective studies
examining whether the DHEA or DHEAS response is implicated
in the development of PTSD have been carried out yet.
In this study, we investigated whether plasma cortisol,
DHEAS and cortisol-to-DHEAS ratio, collected immediately
following traumatic injury, predicted PTSD symptoms at 6
weeks and 6 months post-trauma in a sample of 397 acutely
injured trauma victims. We hypothesized that lower levels of
cortisol predict greater PTSD symptoms at 6 weeks and 6
months. Although the role of DHEAS in the development of
PTSD is yet unclear, we also expected that lower levels of
DHEAS and a smaller cortisol-to-DHEAS ratio predict PTSD
symptoms at 6 weeks and 6 months.
2. Methods and materials
2.1. Subjects and procedure
Patients were recruited between 2005 and 2009 as part of a
large ongoing prospective study of psychopathology following
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two academic level-1 trauma centers in Amsterdam, The
Netherlands, were consecutively included, if they met inclu-
sion criteria of age (18 years and older), having sustained
injuries from a traumatic event (cf. A1-criterion of the DSM
IV PTSD diagnosis), and mastery of the Dutch language.
Patients with injuries due to deliberate self-harm, with an
organic brain condition, current psychotic symptoms or dis-
order, bipolar disorder, depression with psychotic features,
with moderate to severe traumatic brain injury (i.e., Glasgow
Coma Scale (GCS) score of less than 13) (Teasdale and Jennett,
1974), or who permanently resided outside the Netherlands,
were excluded. Medical ethical approval was obtained from
the institutional review boards of the Academic Medical Cen-
ter and Vrije Universiteit medical center. Upon arrival at the
trauma center and at initial medical examination, medical
staff collected blood samples for stress hormone assessment.
Research assistants selected eligible patients from the hospi-
tals’ registrations and contacted them within 72 h of the injury
in-hospital or by telephone for participation. Patients provided
verbal and written informed consent for the psychological
assessments and to analyze the collected blood samples for
stress hormones. All clinical assessments were performed at
the Center for Anxiety Disorders of the Academic Medical
Center, at bedside or at the private home of the patient by
trained master and bachelor level psychologists (for more
details, see Mouthaan et al., 2011).
2.2. Measures
2.2.1. Cortisol and DHEAS
A 4.5 mL cryovial of blood was stored at 80 8C immediately
after collection by the trauma center staff at the patient’s
initial medical assessment. Cortisol and DHEAS levels (in nmol/
L) were analyzed in batch. Cortisol was analyzed by a chemi-
luminiscence assay using the Immulite 2000 (Siemens, Breda,
The Netherlands) with inter-assay and intra-assay coefficients
of variation 5.5 and 8.3%. DHEAS was measured by RIA (Sie-
mens) with inter-assay and intra-assay coefficients of variation
4.4 and 6.3%. Reference values for cortisol levels were
220—650 nmol/L for 8:00 h AM and 100—450 nmol/L for
16:00 h PM. Reference values for DHEAS levels were:
8—17 nmol/L for men below age 30, 2—10 nmol/L for women
below age 30, 3—14 nmol/L for men age 30—50, 1—7 nmol/L
for women age 30—40, .9—7 nmol/L for women age 40—50,
2—8 nmol/L for men age 50—60, .7—5 nmol/L for women
age 50—60, 1—8 nmol/L for men age 60—70, .4—4 nmol/L
for women age 60—70, .8—5 nmol/L for men age 70—80
and .2—1 nmol/L for women age 70—80. Time of day of blood
sampling was registered for each patient. Cortisol-to-DHEAS
ratio was computed by dividing cortisol levels by DHEAS levels.
A smaller cortisol-to-DHEAS ratio indicated lower cortisol
relative to higher DHEAS levels, whereas a higher ratio indi-
cates higher cortisol levels relative to lower DHEAS.
2.2.2. Injury-related characteristics
Injury severity was assessed using the Injury Severity Score
(ISS), a scoring system that provides an overall severity
score for patients with traumatic injuries. The ISS ranges
from 0 (no injury) to 75 (unsurvivable injury) with a score of
16 and higher indicating severe injury (Copes et al., 1990).The Glasgow Coma Scale (GCS) is a neurological scale to
record level of consciousness and consists of three para-
meters: Best Eye Response (four grades), Best Verbal
Response (five grades), Best Motor Response (six grades).
Resulting scores are between 3 (deep unconsciousness) and
15 (fully conscious) (Teasdale and Jennett, 1974). Both ISS
and GCS were assessed by the treating physician at initial
medical examination, and were later generated from the
hospital trauma registration systems.
2.2.3. Posttraumatic stress disorder
The Clinician Administered PTSD Scale (CAPS) (Blake et al.,
1995) was used to assess PTSD symptoms at 6 weeks and 6
months. The CAPS is a 30-item semi-structured interview
for diagnosing PTSD (Weathers et al., 2001). Symptom
severity is determined by adding frequency and intensity
of the 17 symptoms of intrusion, avoidance and hyperar-
ousal (both ranging from 0 to 4, total scores ranging from 0
to 136). The rule of Weathers et al. (1999) was used to
establish a PTSD diagnosis, in which symptoms need at
least a frequency of 1 and intensity of 2 with a total score
of at least 45 points.
2.2.4. Analyses
As part of a longitudinal database with multiple repeated
PTSD assessments, missing data of continuous CAPS outcomes
were replaced using multiple imputation (SPSS 21.0), creat-
ing five different datasets. In this procedure, the fully con-
ditional specification approach was used, in which data were
imputed on a variable-by-variable basis by specifying an
imputation model per variable. This method has been found
to work well in practice (van Buuren, 2011). Independent
samples t-tests and chi-square tests were used to determine
significant associations between demographics and injury-
related characteristics and cortisol, DHEAS and cortisol-to-
DHEAS ratio. For Pearson correlations and multivariate linear
regression analyses, CAPS scores and values for cortisol,
DHEAS and cortisol-to-DHEAS ratio were positively skewed
and were square root-transformed.
We specified 8 separate multivariate linear regression
models for predicting PTSD symptoms. We analyzed whether
independent variables cortisol and DHEAS predicted PTSD
symptoms at 6 weeks (model 1) and 6 months (model 3).
We added gender, age, time of blood sampling, injury sever-
ity, trauma history, and ICU admission as covariates to control
for possible confounding effects in models 2 (for 6 weeks
PTSD) and 4 (for 6 months PTSD). The same procedures were
repeated for cortisol-to-DHEAS ratio as independent vari-
able. In models 5 and 7, we tested whether cortisol-to-DHEAS
ratio predicted PTSD symptoms at 6 weeks (model 5) and 6
months (model 7). We added the above mentioned covariates
gender, age, time of blood sampling, injury severity, trauma
history, and ICU admission to control for possible confounding
effects (model 6 with PTSD symptoms at 6 weeks and model 8
with PTSD symptoms at 6 months as dependent variables).
To examine the role of cortisol, DHEAS and cortisol-to-
DHEAS ratio in predicting a PTSD diagnosis at 6 weeks and 6
months, we performed logistic regression analyses with and
without the above mentioned covariates.
To explore DHEAS’s putative restorative effects, we per-
formed a linear regression analysis of the contribution of
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severity from 6 weeks to 6 months. PTSD change scores were
computed by subtracting CAPS scores at 6 months from CAPS
scores at 6 weeks.
All analyses were carried out in SPSS 19.0 with p-values
<.05 indicating statistical significance.
3. Results
3.1. Participants
Of the 1496 eligible patients who presented at the trauma
centers, 852 patients (57%) consented to participate in the
ongoing prospective study of which blood samples of 397
patients (46.6%) were collected and analyzed. There were no
differences between patients with and without collected
blood samples in age, gender, marital status, educational
background, country of origin, trauma history, traumatic
event, ISS, GCS, time of day of initial medical assessment,Table 1 Sociodemographic and clinical characteristics.
Characteristics N %
Male gender 253 63.7
Married or cohabitating 152 40.2
College or university degree 80 20.2
Country of origin:
Netherlands
314 83.5
Traumatic event:
Traffic accident 272 68.5
Fall from height 48 12.1
Work-related accident 43 10.8
Physical abuse 14 3.5
Other: fire, recreational,
natural disaster,
airplane crash
20 5.0
ICU admission 47 11.8
Time of blood sampling:
Morning (0600—1200 h) 104 28.3
Afternoon (1200—1800 h) 132 35.9
Evening (1800—2400 h) 97 24.4
Night (2400—0600 h) 35 8.8
PTSD diagnosis
at 6 weeks
30 10.3
PTSD diagnosis
at 6 months
14 6.2
Characteristics M SD
Age in years 42.57 15.48
Trauma history 2.92 2.19
ISS 8.76 8.87
GCS 14.40 2.32
Plasma cortisol (nmol/L) 714.74 260.87
Plasma DHEA-S (nmol/L) 4.65 3.40
CAPS at 6 weeks 21.17 18.51
CAPS at 6 months 16.33 15.23
PTSD, posttraumatic stress disorder; ISS, injury severity score;
GCS, Glasgow Coma Score; DHEA-S, dehydroepiandrosterone-
sulfate; ICU, intensive care unit; CAPS, Clinician Administered
PTSD Scale.or PTSD symptoms at 6 weeks or 6 months. Table 1 shows the
sociodemographic and clinical characteristics of the 397
participants. The 6 week and 6 month assessments of PTSD
symptoms took place at mean 52.3 days (SD = 26.0, n = 291,
73.3%) and 214.2 days (SD = 36.1, n = 226, 56.9%). Patients
not assessed for PTSD at 6 months did not differ from those
who were assessed on any of the before mentioned back-
ground or clinical characteristics. PTSD prevalence was 10.3%
(n = 30) at 6 weeks and 6.2% (n = 14) at 6 months.
3.2. Univariate analyses of cortisol and DHEAS
Means and standard deviations for cortisol and DHEAS are
displayed in Table 1. Compared to the reference values,
cortisol levels were increased in 76% (n = 281) of patients
and decreased in 1.4% (n = 5). DHEAS was increased in 6.5%
(n = 5) and decreased in 24% (n = 91). Cortisol and DHEAS
were positively correlated (r = .18, p < .001, n = 390).
Cortisol (F (3,364) = 2.26, p = .08) and DHEAS levels
(F (3,357) = 1.68, p = .17) were not significantly associated
with time of day of blood sampling. Cortisol-to-DHEAS ratio,
however, was significantly greater during the afternoon
compared to evening (F (3,357) = 4.45, p = .004, mean
difference = 81.42, SD = 29.80) and nighttime (mean differ-
ence = 133.51, SD = 41.85), indicating higher cortisol relative
to lower DHEAS in the afternoon compared to lower cortisol
versus higher DHEAS in the evening and night.
Patients who were older (r = .17, p = .001, n = 397),
severely injured (ISS  16; t (341) = 5.04, p < .001), hospi-
talized (t (381) = 5.82, p < .001), and patients who were
injured due to falling from a height (F (4,392) = 4.94,
p = .001), had higher mean cortisol levels. DHEAS levels were
negatively associated with age (r = .39, p < .001, n = 390)
and female gender (t (388) = 4.81, p < .001). Higher cortisol-
to-DHEAS ratios were found for women than for men
(t (388) = 3.62, p < .001) and for hospitalized versus
non-hospitalized patients (t (374) = 2.16, p = .03).
Cortisol-to-DHEAS ratio was positively correlated with age
(r = .45, p < .001, n = 390).
3.3. Prediction of PTSD symptoms
Table 2 presents the predictive values of acute cortisol and
DHEAS for 6 weeks and 6 months PTSD symptoms. Lower
cortisol and higher DHEAS both significantly predicted
PTSD symptoms at 6 weeks (model 1). At 6 months, only
lower cortisol was a significant predictor of PTSD symptoms
(model 3). Cortisol accounted for 2% of the total explained
variance for 6-week PTSD symptoms in models 1 and 3.
After controlling for the effects of age, gender, time of blood
sampling, injury, trauma history, and ICU admission, lower
cortisol remained a significant predictor for PTSD symptoms
at 6 weeks (model 2) and 6 months (model 4), but DHEAS
showed no effects. The outcomes of the models with corti-
sol-to-DHEAS ratio as a predictor are shown in Table 3.
A smaller cortisol-to-DHEAS ratio significantly predicted PTSD
symptoms at 6 weeks (model 5), but not anymore after
inclusion of the covariates (model 6), and not at 6 months
(models 7 and 8).
Logistic regression analyses for acute and chronic PTSD
diagnoses showed no significant odd’s ratios (OR) for cortisol
Table 2 Predictive values of acute cortisol and DHEAS for 6 week and 6 month PTSD symptoms with and without control variables.
PTSD symptoms 6 weeks PTSD symptoms 6 months
Model 1: R2 = .03 Model 2: R2 = .09 Model 3: R2 = .01 Model 4: R2 = .06
Cortisol .14 ** .15 * .12 * .16 *
DHEAS .12 * .10 .05 .05
Gender .20** .14 *
Age .05 .01
Morning .04 .04
Evening .12 .06
Night .12 .08
ISS .09 .12
Trauma history .18* .19 **
ICU admission .02 .03
PTSD, posttraumatic stress disorder; DHEAS, dehydroepiandrosterone-sulfate; ISS, injury severity score; ICU, intensive care unit.
N.B. Beta values of multivariate regression analyses of PTSD symptoms at 6 weeks and 6 months by cortisol and DHEAS with and without
controlling for gender, age, time of blood sampling, injury severity score, trauma history, and ICU admission.
* p < .05.
** p < .01.
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OR = .95, 95% CI [.87—1.03], p = .24), DHEAS (6 weeks:
OR = 1.24, 95% CI [.76—2.00], p = .39; 6 months: OR = 1.04,
95% CI [.48—2.22], p = .93), or cortisol-to-DHEAS ratio (6
weeks: OR = .98, 95% CI [.92—1.04], p = .44; 6 months:
OR = .98, 95% CI [.91—1.07], p = .69).
Lastly, change in PTSD symptoms between 6 weeks and 6
months was not significantly predicted by acute DHEAS,
controlling for age and gender (b = .10, t = 1.47, p = .15;
adjusted R2 = .02, F (3,316) = 3.29, p = .03).
4. Discussion
This study showed that lower plasma cortisol levels in injured
patients assessed at the trauma resuscitation room predicted
acute and chronic PTSD symptoms, even after controlling
for age, gender, time of blood sampling, injury, trauma
history, and ICU admission. Higher acute DHEAS levels andTable 3 Predictive values of acute cortisol-to-DHEAS ratio for 6
variables.
PTSD symptoms 6 weeks 
Model 5: R2 = .03 Model 6
Cortisol-to-DHEAS ratio .16 ** .13 
Gender .19 **
Age .05 
Morning .04 
Evening .12 
Night .13 
ISS .04 
Trauma history .18**
ICU admission .01 
PTSD, posttraumatic stress disorder; DHEAS, dehydroepiandrosterone-
N.B. Beta values of multivariate regression analyses of PTSD symptoms a
controlling for gender, age, time of blood sampling, injury severity sc
* p < .05.
** p < .01.a smaller cortisol-to-DHEAS ratio contributed to 6 week PTSD
symptoms, but not after controlling for the same factors, and
not at 6 months. There were no significant effects of cortisol,
DHEAS or cortisol-to-DHEAS ratio on acute or chronic PTSD
diagnoses. Lastly, DHEAS did not contribute significantly to
PTSD symptom change between 6 weeks and 6 months.
In line with previous studies (Aardal-Eriksson et al., 2001;
Delahanty et al., 2000; Ehring et al., 2008; McFarlane et al.,
2011), our findings confirm the hypothesis that the develop-
ment of PTSD may partly be explained by dysfunctioning of
the HPA-axis. Moreover, we extended previous results by
showing that cortisol is not only a predictor for acute PTSD
symptoms, but continues to predict chronic PTSD symptoms
at 6 months, even when controlling for relevant trauma and
injury characteristics. As proposed, lower levels of circulat-
ing cortisol likely prolong the adrenergic response,
thereby strengthening the consolidation of the fear memory
(Yehuda, 2002). Recent research has also implicated cortisol
in the expression of genes relevant to PTSD, such as FKBP5, week and 6 month PTSD symptoms with and without control
PTSD symptoms 6 months
: R2 = .09 Model 7: R2 = .01 Model 8: R2 = .05
.10 .11
.14 *
.00
.04
.06
.08
.06
.19 **
.01
sulfate; ISS, injury severity score; ICU, intensive care unit.
t 6 weeks and 6 months by cortisol-to-DHEAS ratio with and without
ore, trauma history, and ICU admission.
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for a review), which points to the necessity for a more
comprehensive viewpoint of the influence of stress hormones
in general, and cortisol in particular, in the onset of PTSD.
As a biomarker for subsequent PTSD symptoms, acute cortisol
levels in itself are an interesting target, as they are easily
obtainable in injured populations seeking medical assistance
and demonstrated a stable effect on acute and chronic PTSD
symptoms in our study. However, it is still questionable to
what extent acute cortisol levels could predict which indi-
viduals go on to develop or not develop PTSD (i.e., positive
and negative predictive value), which pertains to the
limited variance of PTSD severity explained by acute cortisol
as found in our study. In addition, the RIA antibody method
used to measure cortisol in our study also may have been
suboptimal due to lack of specificity. A recent study using a
standard cortisol radioimmunoassay suggested that low cor-
tisol levels predicted poor treatment outcome, whereas
use of a more accurate mass spectrometry methodology
that measures cortisol and its metabolites separately showed
that low levels of a reduced metabolite of cortisol
produced by 5alpha reductase, rather than low cortisol,
actually predicted poor outcome (Yehuda et al., 2009).
Note that 5alpha reductase is also involved in the production
of GABAergic reduced metabolite of progesterone (e.g. allo-
pregnanolone) and testosterone (androsterone), both
considered to have a conceivable role in PTSD risk
(Gillespie et al., 2013).
To the best of our knowledge, our study was the first to
investigate the role of DHEAS in the prediction of acute and
chronic PTSD. In line with previous cross-sectional studies
(Gill et al., 2008; Jogems-Kosterman et al., 2007; Yehuda
et al., 2006), higher DHEAS and a smaller cortisol-to-DHEAS
ratio were associated with PTSD symptoms at 6 weeks,
although not after controlling for background and injury
characteristics. Cross-sectional and longitudinal studies on
DHEA(-S) and PTSD so far produced highly mixed results,
which could indicate a dual effect or performance of
DHEA(-S) in trauma-exposed people. This was found in
one longitudinal study of refugees: over time, negative
events were associated with increases in DHEAS in refugees
with PTSD and with decreases in DHEAS levels in those
without PTSD (Sondergaard and Theorell, 2003). Moreover,
an interaction effect was found between PTSD and depres-
sion: in depressed subjects, lower DHEAS was found
for PTSD versus non-PTSD, whereas in non-depressed sub-
jects, higher DHEAS was found in PTSD versus non-PTSD
(Sondergaard et al., 2002). As DHEA responses are
more marked than DHEAS responses to acute stress
(Lennartsson et al., 2012), it is possible that DHEA could
have played a larger predictive role in our study than
DHEAS did. More research is needed to determine the
usefulness of DHEA versus DHEAS as a biomarker for sub-
sequent PTSD symptomatology, for example in populations
with a higher PTSD prevalence rate, such as victims of
rape, combat or interpersonal violence.
This study is the first to show a predictive effect of plasma
cortisol, whereas previous studies finding predictive effects
for cortisol used saliva or urine samples (Aardal-Eriksson
et al., 2001; Delahanty et al., 2000; Ehring et al., 2008;
McFarlane et al., 2011). It is possible that our larger sample
provided sufficient power for the analyses. Second, it ispossible that the timing of our blood draw, within hours of
the traumatic event for the entire participant sample, pro-
vided sufficient opportunity to witness the acute stress
response of the survivors.
In our sample, all patients had endured a physical trauma
with the possibility of severe injury. As in previous studies in
similar populations (Delahanty et al., 2003; Woolf, 1992),
injury severity was significantly positively correlated with
acute cortisol levels. It is unclear to what extent our findings
may be generalizable to populations without possible severe
injury, such as victims of war or rape. However, since we
included injury severity as a confounding variable in our ana-
lyses, our results show that acute cortisol was an independent
predictor for consequent PTSD. Future studies should examine
whether acute cortisol displays similar predictive effects on
PTSD for injured versus non-injured trauma survivors.
Strengths of our study are that we included a relatively
large sample of 397 injured patients, who were assessed at
several occasions following trauma using clinical interviews.
Limitations may be that blood samples were collected in only
half of our originally included sample. A large proportion of
blood samples were missing, most likely due to uninformed
hospital staff, use of the blood samples for medical reasons or
technical problems in conservation, preparation, transport or
laboratory processing. Although our final sample did not differ
from the larger sample with respect to baseline variables,
selection bias cannot be ruled out. A similar concern is the
attrition at follow-up of 22%. Further, although we collected
and controlled for various important covariates, among which
trauma history, injury severity and ICU admission, we did not
account for other possible confounders, such as nicotine use,
oral contraceptive use, experienced pain or alcohol or drug use
at the time of blood sampling. Nicotine and oral contraceptives
have been shown to suppress cortisol reactivity (Fu et al.,
2007; Reynolds et al., 2013). Alternately, pain, alcohol and
opiate drug use were found to increase the cortisol response to
acute stress (Coventry et al., 2001; Ehring et al., 2008;
Stankiewicz et al., 2013). Furthermore, studies have shown
that smoking is an independent risk factor for mental health
problems in a post-disaster sample (Olff et al., 2006; van der
Velden et al., 2007), and pain moderates the relationship
between cortisol and the development of PTSD in a sample
of injury victims (Ehring et al., 2008). Since we had no infor-
mation about these variables, we do not know whether they
may have influenced the association between cortisol level
and PTSD symptoms. Finally, we measured cortisol and DHEAS
at only one occasion and had no information on day curves of
stress hormones.
Future studies may be focused on elucidating whether low
cortisol and increased DHEAS levels are pre-trauma vulner-
ability factors for PTSD or associated with the trauma.
Moreover, while psychotherapy may be associated with
restoring HPA-axis abnormalities (Olff et al., 2007), inter-
ventions targeting the HPA-axis more directly by glucocorti-
coid augmentation are promising (Yehuda et al., 2010).
A recent pilot study on hydrocortisone administration imme-
diately after trauma shows promise to the prevention of the
development of PTSD (Zohar et al., 2011).
In summary, our study provides important new evidence
on the crucial role of the HPA-axis in response to trauma by
showing that cortisol and DHEAS levels predict PTSD symp-
toms in survivors of recent trauma.
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